A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease

BACKGROUND: In preclinical studies, p38⍺ kinase is implicated in Alzheimer’s disease (AD) pathogenesis. In animal models, it mediates impaired synaptic dysfunction in the hippocampus, causing memory deficits, and is involved in amyloid-beta (Aβ) production and tau pathology. METHODS: The REVERSE-SD...

Descripción completa

Detalles Bibliográficos
Autores principales: Prins, Niels D., Harrison, John E., Chu, Hui-May, Blackburn, Kelly, Alam, John J., Scheltens, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157623/
https://www.ncbi.nlm.nih.gov/pubmed/34044875
http://dx.doi.org/10.1186/s13195-021-00843-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157623/
https://www.ncbi.nlm.nih.gov/pubmed/34044875
http://dx.doi.org/10.1186/s13195-021-00843-2

Ejemplares similares